The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

BACKGROUND: While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Lucas, David M., Alinari, Lapo, West, Derek A., Davis, Melanie E., Edwards, Ryan B., Johnson, Amy J., Blum, Kristie A., Hofmeister, Craig C., Freitas, Michael A., Parthun, Mark R., Wang, Dasheng, Lehman, Amy, Zhang, Xiaoli, Jarjoura, David, Kulp, Samuel K., Croce, Carlo M., Grever, Michael R., Chen, Ching-Shih, Baiocchi, Robert A., Byrd, John C.
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2010
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2880605/
https://ncbi.nlm.nih.gov/pubmed/20532179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0010941
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים